EPS for GlaxoSmithKline plc (ADR) (GSK) Expected At $0.71

July 17, 2017 - By Louis Casey

 EPS for GlaxoSmithKline plc (ADR) (GSK) Expected At $0.71

Wall Street await GlaxoSmithKline plc (ADR) (NYSE:GSK) to release earnings on July, 26. Analysts forecast earnings per share of $0.71, up exactly $0.01 or 1.43 % from 2014’s $0.7 EPS. The expected GSK’s profit could reach $1.71B giving the stock 14.90 P/E in the case that $0.71 earnings per share is reported. After posting $0.62 EPS for the previous quarter, GlaxoSmithKline plc (ADR)’s analysts now forecast 14.52 % EPS growth. It is down 4.26% since July 18, 2016 and is uptrending. It has underperformed by 12.44% the S&P500.

GlaxoSmithKline plc (ADR) (NYSE:GSK) Ratings Coverage

Among 14 analysts covering GlaxoSmithKline (NYSE:GSK), 7 have Buy rating, 0 Sell and 7 Hold. Therefore 50% are positive. GlaxoSmithKline had 21 analyst reports since September 8, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Tuesday, October 20 by Credit Suisse. The company was upgraded on Monday, October 12 by JP Morgan. The firm has “Buy” rating given on Friday, May 26 by Berenberg. The rating was maintained by Argus Research on Monday, December 7 with “Buy”. Argus Research maintained the stock with “Buy” rating in Friday, August 12 report. The firm has “Neutral” rating given on Tuesday, September 15 by BNP Paribas. Investec initiated the stock with “Buy” rating in Thursday, October 20 report. The rating was initiated by Piperjaffray on Friday, September 23 with “Overweight”. The company was upgraded on Wednesday, January 27 by Bryan Garnier & Cie. The stock has “Hold” rating by Cantor Fitzgerald on Friday, February 26.

GlaxoSmithKline plc is a global healthcare company. The company has market cap of $101.75 billion. The Firm operates through three divisions: Pharmaceuticals, Vaccines and Consumer Healthcare. It has a 47.2 P/E ratio. The Firm focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus /infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Another recent and important GlaxoSmithKline plc (ADR) (NYSE:GSK) news was published by Benzinga.com which published an article titled: “Healthcare Repeal Bad For GlaxoSmithKline, Other HIV Treatment Stocks” on July 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: